Citations

Citations to this article as recorded by  

• Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
  Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović, Antonio Simone Laganà
  Biomedicines.2024; 12(3): 653.     CrossRef
• Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review
  Fulvio Cacciapuoti, Ciro Mauro, Valentina Capone, Angelo Sasso, Luca Gaetano Tarquinio, Federico Cacciapuoti
  Heart and Mind.2024;[Epub]     CrossRef
• BRCC36 regulates β-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease
  Yalan Li, Xiaoyue Chen, Yiqing Xiong, Xueqiang Xu, Caidie Xie, Min Min, Dongmei Liang, Cheng Chen, Huijuan Mao
  Journal of Translational Medicine.2024;[Epub]     CrossRef
• Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study
  Vedant Agrawal, Saketh Amasa, Mert Karabacak, Konstantinos Margetis
  Neurosurgery.2024;[Epub]     CrossRef

Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.

Citations

Citations to this article as recorded by  

• Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
  Jia Nuo Feng, Tianru Jin
  Medical Review.2024; 4(4): 312.     CrossRef
• Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
  Subhodip Pramanik, Partha Pal, Sayantan Ray
  World Journal of Methodology.2024;[Epub]     CrossRef
• Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
  Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Assessing the therapeutic potential of long-chain isomaltooligosaccharides in diabetic and hyperlipidemic rats
  Onrapak Reamtong, Rattiya Waeonukul, Pattaneeya Prangthip
  Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
• Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease
  Samradhi Singh, Mona Kriti, Roberto Catanzaro, Francesco Marotta, Mustafa Malvi, Ajay Jain, Vinod Verma, Ravinder Nagpal, Rajnarayan Tiwari, Manoj Kumar
  Livers.2024; 4(3): 435.     CrossRef
• Second Generation Anti-Obesity Medications
  Sri Nikhita Chimatapu, Steven D. Mittelman, Vibha Singhal
  Current Pediatrics Reports.2024; 12(4): 138.     CrossRef
• The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
  Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
  Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 784.     CrossRef
• GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
  Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
  International Journal of Molecular Sciences.2023; 24(2): 1703.     CrossRef
• From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
  Avilene Rodríguez-Lara, Ascensión Rueda-Robles, María José Sáez-Lara, Julio Plaza-Diaz, Ana I. Álvarez-Mercado
  Pathogens.2023; 12(7): 940.     CrossRef
• Investigating the Opposing Effect of Two Different Green Tea Supplements on Oxidative Stress, Mitochondrial Function and Cell Viability in HepG2 Cells
  Aparna Shil, Chris Davies, Lata Gautam, Justin Roberts, Havovi Chichger
  Journal of Dietary Supplements.2022; 19(4): 459.     CrossRef
• Antiobesity therapeutics with complementary dual‐agonist activities at glucagon and glucagon‐like peptide 1 receptors
  Bong Gyu Park, Gyeong Min Kim, Hye‐Jin Lee, Jae Ha Ryu, Dong‐Hoon Kim, Jae‐Young Seong, Soojeong Kim, Zee‐Yong Park, Young‐Joon Kim, Jaemin Lee, Jae Il Kim
  Diabetes, Obesity and Metabolism.2022; 24(1): 50.     CrossRef
• The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
  Juan Pang, Jia Nuo Feng, Wenhua Ling, Tianru Jin
  Acta Pharmaceutica Sinica B.2022; 12(11): 4040.     CrossRef
• Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes
  Jinsoo Song, In-Jeoung Baek, Sujeong Park, Jinjoo Oh, Deokha Kim, Kyung Song, Mi Kyung Kim, Hye Won Lee, Byoung Kuk Jang, Eun-Jung Jin
  iScience.2022; 25(10): 105135.     CrossRef
• Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
  Salvatore Pezzino, Maria Sofia, Gloria Faletra, Chiara Mazzone, Giorgia Litrico, Gaetano La Greca, Saverio Latteri
  Biology.2022; 11(11): 1622.     CrossRef
• Efficacy and safety of semaglutide for weight management: evidence from the STEP program
  Anastassia Amaro, Danny Sugimoto, Sean Wharton
  Postgraduate Medicine.2022; 134(sup1): 5.     CrossRef
• Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
  Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański
  Nutrients.2021; 13(2): 351.     CrossRef
• Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
  Julio Plaza-Díaz, Patricio Solis-Urra, Jerónimo Aragón-Vela, Fernando Rodríguez-Rodríguez, Jorge Olivares-Arancibia, Ana I. Álvarez-Mercado
  Biomedicines.2021; 9(2): 145.     CrossRef
• A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases
  Changlu Qi, Ping Wang, Tongze Fu, Minke Lu, Yiting Cai, Xu Chen, Liang Cheng
  Briefings in Functional Genomics.2021; 20(1): 42.     CrossRef
• Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
  Maka Siamashvili, Stephen N. Davis
  Expert Review of Clinical Pharmacology.2021; 14(9): 1081.     CrossRef
• Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD
  Manisha Gupta, Pawan Krishan, Amarjot Kaur, Sandeep Arora, Nirupma Trehanpati, Thakur Gurjeet Singh, Onkar Bedi
  Inflammation Research.2021; 70(7): 765.     CrossRef
• Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India
  Nithyanantham Kamalraj, Madhanagopal Sathishkumar, Mani Arunvignesh, Viswanathan Baskar, Saravanan Jebarani, Anandakumar Amutha, Mohan Deepa, Coimbatore Subramanyam Shanthi Rani, Sundaramoorthy Chandru, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Mardavada
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(5): 102261.     CrossRef
• Gastrointestinal Hormones in Healthy Adults: Reliability of Repeated Assessments and Interrelations with Eating Habits and Physical Activity
  Silke M. Wortha, Katharina A. Wüsten, Veronica A. Witte, Nicole Bössel, Wolfram Keßler, Antje Vogelgesang, Agnes Flöel
  Nutrients.2021; 13(11): 3809.     CrossRef
• Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes
  Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Seisuke Sato, Toshihiro Kobayashi, Tao Dong, Takanobu Saheki, Mari Matsumoto, Hisakazu Iwama, Huanxiang Zhang, Koji Murao
  Molecular Metabolism.2020; 34: 16.     CrossRef
• Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials
  Amir Hadi, Ehsan Ghaedi, Saman Khalesi, Makan Pourmasoumi, Arman Arab
  European Journal of Nutrition.2020; 59(7): 2857.     CrossRef
• Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
  Xiaodan Lv, Yongqiang Dong, Lingling Hu, Feiyu Lu, Changyu Zhou, Shaoyou Qin
  Endocrinology, Diabetes & Metabolism.2020;[Epub]     CrossRef
• Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
  Jong Youl Lee, Taehoon Park, Eunmi Hong, Reeju Amatya, Kyung-Ah Park, Young-Hoon Park, Kyoung Ah Min, Minki Jin, Sumi Lee, Seungmi Hwang, Gu Seob Roh, Meong Cheol Shin
  Biomaterials.2020; 257: 120250.     CrossRef
• A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
  Rebecca K. Vincent, David M. Williams, Marc Evans
  Diabetes, Obesity and Metabolism.2020; 22(12): 2227.     CrossRef
• A systematic review and meta-analysis of probiotic consumption and metabolic status of athletes
  Atefeh As’Habi, Maryam Nazari, Hossein Hajianfar, Arman Arab, Zeinab Faghfoori
  International Journal of Food Properties.2020; 23(1): 941.     CrossRef
• The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage
  Julio Plaza-Díaz, Patricio Solís-Urra, Fernando Rodríguez-Rodríguez, Jorge Olivares-Arancibia, Miguel Navarro-Oliveros, Francisco Abadía-Molina, Ana I. Álvarez-Mercado
  International Journal of Molecular Sciences.2020; 21(21): 8351.     CrossRef
• Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
  L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská
  Frontiers in Endocrinology.2020;[Epub]     CrossRef
• Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of diabetes
  Michael J. Ryan
  Clinical Science.2020; 134(23): 3119.     CrossRef
• Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
  Maite Martínez-Uña, Yaiza López-Mancheño, Carlos Diéguez, Manuel A. Fernández-Rojo, Marta G. Novelle
  International Journal of Molecular Sciences.2020; 21(24): 9368.     CrossRef
• The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
  Cindy G. Avalos-de León, Mónica B. Jiménez-Castro, María Eugenia Cornide-Petronio, Araní Casillas-Ramírez, Carmen Peralta
  Cells.2019; 8(12): 1599.     CrossRef
• LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet
  Tao Hao, Hongying Chen, Sisi Wu, Haoming Tian
  Molecular Medicine Reports.2019;[Epub]     CrossRef
• Liraglutide alters hepatic metabolism in high-fat fed obese mice: A bioinformatic prediction and functional analysis
  Isabelle Arruda Barbosa, Eloá Mangabeira Santos, Alanna Fernandes Paraíso, Pablo Vinicyus Ferreira Chagas, Luís Paulo Oliveira, João Marcus Oliveira Andrade, Lucyana Conceição Farias, Bruna Mara Aparecida de Carvalho, Alfredo Maurício Batista de Paula, An
  Meta Gene.2019; 20: 100553.     CrossRef
• Dipeptidyl peptidase‐4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats
  Nagat Younan, Samah Elattar, Mira Farouk, Laila Rashed, Suzanne Estaphan
  Physiological Reports.2019;[Epub]     CrossRef
• Microbial Metabolites Determine Host Health and the Status of Some Diseases
  Panida Sittipo, Jae-won Shim, Yun Lee
  International Journal of Molecular Sciences.2019; 20(21): 5296.     CrossRef
• Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats
  Yoo-Cheol Hwang, Da-Hee Oh, Moon Chan Choi, Sang Yeoul Lee, Kyu-Jeong Ahn, Ho-Yeon Chung, Sung-Jig Lim, Sung Hyun Chung, In-Kyung Jeong
  The Korean Journal of Internal Medicine.2018; 33(2): 347.     CrossRef
• Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers
  Ahmed A. Abdelsameea, Noha A.T. Abbas, Samar M. Abdel Raouf
  Naunyn-Schmiedeberg's Archives of Pharmacology.2017; 390(3): 311.     CrossRef
• Natural alkaloid bouchardatine ameliorates metabolic disorders in high‐fat diet‐fed mice by stimulating the sirtuin 1/liver kinase B‐1/AMPK axis
  Yong Rao, Hong Yu, Lin Gao, Yu‐Ting Lu, Zhao Xu, Hong Liu, Lian‐Quan Gu, Ji‐Ming Ye, Zhi‐Shu Huang
  British Journal of Pharmacology.2017; 174(15): 2457.     CrossRef
• Non-alcoholic fatty liver disease and dyslipidemia: An update
  Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros
  Metabolism.2016; 65(8): 1109.     CrossRef
• Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
  Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
  PLOS ONE.2016; 11(12): e0166913.     CrossRef
• The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter
  Young Eun Chon, Kwang Joon Kim, Kyu Sik Jung, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Jae Bock Chung, Kyeong Hye Park, Ji Cheol Bae, Kwang-Hyub Han
  Yonsei Medical Journal.2016; 57(4): 885.     CrossRef
• The role of the gut microbiota in NAFLD
  Christopher Leung, Leni Rivera, John B. Furness, Peter W. Angus
  Nature Reviews Gastroenterology & Hepatology.2016; 13(7): 412.     CrossRef
• Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR)
  Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard
  Physiological Reports.2016;[Epub]     CrossRef
• A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence
  Jonathan Temple, Paul Cordero, Jiawei Li, Vi Nguyen, Jude Oben
  International Journal of Molecular Sciences.2016; 17(6): 947.     CrossRef
• Extrapancreatic Effect of Glucagon like Peptide-1
  In-Kyung Jeong
  The Korean Journal of Medicine.2015; 89(4): 404.     CrossRef
• Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet
  Aline B. Santamarina, Juliana L. Oliveira, Fernanda P. Silva, June Carnier, Laís V. Mennitti, Aline A. Santana, Gabriel H. I. de Souza, Eliane B. Ribeiro, Cláudia M. Oller do Nascimento, Fábio S. Lira, Lila M. Oyama, Patricia Aspichueta
  PLOS ONE.2015; 10(11): e0141227.     CrossRef
• Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1
  Mark F McCarty, James J DiNicolantonio
  Open Heart.2015; 2(1): e000205.     CrossRef
• The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease
  Huiting Gao, Zhigang Zeng, Han Zhang, Xiaoli Zhou, Lichang Guan, Weiping Deng, Lishu Xu
  Biological & Pharmaceutical Bulletin.2015; 38(5): 694.     CrossRef
• Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
  Sri Harsha Tella, Marc S. Rendell
  Therapeutic Advances in Endocrinology and Metabolism.2015; 6(3): 109.     CrossRef
• Gut Microbiota: Association with NAFLD and Metabolic Disturbances
  E. Lau, D. Carvalho, P. Freitas
  BioMed Research International.2015; 2015: 1.     CrossRef
• Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes
  James J DiNicolantonio, Jaikrit Bhutani, James H O'Keefe
  Open Heart.2015; 2(1): e000327.     CrossRef
• Nonalcoholic fatty liver disease and bariatric surgery in adolescents
  AiXuan Holterman, Juan Gurria, Smita Tanpure, Nerina DiSomma
  Seminars in Pediatric Surgery.2014; 23(1): 49.     CrossRef
• Pediatric non-alcoholic fatty liver disease: New insights and future directions
  Pierluigi Marzuillo
  World Journal of Hepatology.2014; 6(4): 217.     CrossRef
• 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics
  Francesca Maria Trovato, Daniela Catalano, Giuseppe Musumeci, Guglielmo M Trovato
  EPMA Journal.2014;[Epub]     CrossRef
• The Role of Medications for the Management of Patients with NAFLD
  Natalia Mazzella, Laura M. Ricciardi, Arianna Mazzotti, Giulio Marchesini
  Clinics in Liver Disease.2014; 18(1): 73.     CrossRef
• Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis
  A. Alisi, G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giammaria, L. Reali, F. Anania, V. Nobili
  Alimentary Pharmacology & Therapeutics.2014; 39(11): 1276.     CrossRef
• The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
  Mark F McCarty, James J DiNicolantonio
  Open Heart.2014; 1(1): e000103.     CrossRef
• Pediatric non-alcoholic fatty liver disease: an increasing public health issue
  S. Berardis, E. Sokal
  European Journal of Pediatrics.2014; 173(2): 131.     CrossRef
• Glucagon‐like peptide‐1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
  H. Kahal, G. Abouda, A. S. Rigby, A. M. Coady, E. S. Kilpatrick, S. L. Atkin
  Clinical Endocrinology.2014; 81(4): 523.     CrossRef
• Comparative analysis of plasma metabolomics response to metabolic challenge tests in healthy subjects and influence of the FTO obesity risk allele
  Simone Wahl, Susanne Krug, Cornelia Then, Anna Kirchhofer, Gabi Kastenmüller, Tina Brand, Thomas Skurk, Melina Claussnitzer, Cornelia Huth, Margit Heier, Christa Meisinger, Annette Peters, Barbara Thorand, Christian Gieger, Cornelia Prehn, Werner Römisch-
  Metabolomics.2014; 10(3): 386.     CrossRef
• Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
  Eugene Chang, Cheol‐Young Park, Sung Woo Park
  Journal of Diabetes Investigation.2013; 4(6): 517.     CrossRef
• Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions
  Pietro Vajro, Selvaggia Lenta, Claudio Pignata, Mariacarolina Salerno, Roberta D’Aniello, Ida De Micco, Giulia Paolella, Giancarlo Parenti
  Italian Journal of Pediatrics.2012; 38(1): 55.     CrossRef